Stocks
Fate Therapeutics (FATE) EBITDA margin US GAAP (year values) |
|||||||||
| 2019 | 2020 | 2021 | 2022 | 2023 | LTM ? | CAGR 5 years ? | |||
| EBITDA margin, % | ? | -882.1% | -397.7% | -378.1% | -305.9% | -271.1% | -1 325% | ||
| Changes by years, y/y, % | +487pp | +484pp | +20pp | +72pp | +35pp | -27.7% | |||
Fate Therapeutics. EBITDA margin, %
Fate Therapeutics. EBITDA margin, changes, pp
Fate Therapeutics (FATE) EBITDA margin US GAAP (quarter values) |
||||||||
| 2023Q3 | 2023Q4 | 2024Q1 | 2024Q2 | 2024Q3 | LTM ? | |||
| EBITDA margin, % | ? | -2 394% | -2 341% | -2 402% | -596.0% | -1 704% | -1 325% | |
| Changes by years, y/y, % | -1 839pp | -2 196pp | -2 361pp | +5 631pp | +690pp | |||
| Changes by quarters, q/q, % | +3 833pp | +53pp | -61pp | +1 806pp | -1 108pp | |||
